ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1872

Differentiating Primary Central Nervous System Vasculitis from Non-inflammatory Intracranial Vasculopathy
Abstract Number: 1873

The Importance of Lower Extremity Vein Wall Thickness in Patients with Behcet’s Syndrome
Abstract Number: 1874

Using 18F-fluorodeoxyglucose Positron Emission Tomography to Standardize Clinical Trial Recruitment in Takayasu’s Arteritis
Abstract Number: 1875

Hyoscine Butylbromide Inhibits Neutrophil Cell Death Induction by Cocaine-levamisole. a Proof of Concept for the Management of Vasculopathy Induced by Cocaine-Levamisole
Abstract Number: 1876

A Prospective Observational Cohort Study and Systematic Review of 40 Patients with Mouth and Genital Ulcers with Inflamed Cartilage (MAGIC) Syndrome
Abstract Number: 1877

Takayasu Arteritis Patients with Tuberculosis Have Unique Clinical Characteristics
Abstract Number: 1878

Tocilizumab in Caucasian Patients with Takayasu Arteritis: Multicenter Study of 54 Patients
Abstract Number: 1879

Delayed Diagnosis of IgG4 Related Disease Is Associated with Worse Outcome: A Retrospective, Real-life Observational Study
Abstract Number: 1880

Description of an Internet-Based Cohort with a Self-Reported Diagnosis of Polyarteritis Nodosa
Abstract Number: 1881

Surgical Outcomes After Operative Procedures in Patients with Behcet’s Disease
Abstract Number: 1882

Clinical Characteristics and Reliability of a Self-Reported Diagnosis of Large-Vessel Vasculitis
Abstract Number: 1883

Neuro-Behcet’s Disease: 20 Years Single Center Experience of Cyclophosphamide for Induction of Remission
Abstract Number: 1884

Real-life Data for the Use of Anti-TNF Treatment in DADA2
Abstract Number: 1885

Biological Therapy in Refractory Neurobehçet’s Disease. Multicenter Study of 42 Patients
Abstract Number: 1886

Validation of Angiographic Patterns of Disease in a Turkish Cohort of Patients with Takayasu’s Arteritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].